Prospective study on radiation dose escalation in the treatment of squamous cell carcinoma of oesophagus with definitive concurrent chemo-radiation using three-dimensional conformal radiation therapy
Abstract
Background: Poor local control and survival rates associated with radiation and chemotherapy in the management of locally advanced carcinoma of oesophagus have encouraged use of radiation dose escalation. This study analysed outcome and tolerance of radiation dose escalation with concurrent chemotherapy in non-metastatic squamous cell carcinoma of oesophagus.
Materials and Methods: Patients diagnosed with stage I-III squamous cell carcinoma oesophagus, intended to be treated with radical chemo-radiation, between August 2015 to August 2017 were included in this prospective study. Baseline endoscopy, oral intake score and FACT E-QOL score were documented. Patients were treated with radiation dose of 60Gy in 2Gy per fraction schedule (initial 46Gy followed by 14Gy boost to tumour alone) with concurrent 3-weekly 5-FU/Cisplatin or weekly Cisplatin alone regimen.
Results: Out of total of 20 eligible patients with median age of 64 years, majority had middle thoracic oesophageal tumour (60%), grade 2 dysphagia (75%) on oral intake scale. Patients with tumour length of ≤5cm (55%) or >5cm (45%) were categorised. Majority patients (85%) showed complete response at 3 months post treatment. The oral intake score and quality of life improved in 55% and 85%of the patients, respectively. Ten patients had disease progression with 40% of patients showing disease recurrence. No patient developed oesophageal fistula, radiation-pneumonitis or cardiac toxicity. Median disease-free survival and overall survival was 16 months (95% CI, 10-21 months) and 28 months (95% CI, 13-42 months) with 1-year and 2-year survival rates of 72.4% and 53.7%, respectively.
Conclusion: Radiation dose escalation with concurrent chemotherapy in the management of stage I-III, non-metastatic squamous cell carcinoma oesophagus yields a good local control rate at 3 months with less severe complications and improved quality of life.
Downloads
References
Globocan 2018 world fact sheet Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf [Accessed on 06 September 2019].
Nishimura Y, Mitsumori M, Hiraoka M, Koike R, Nakamatsu K, Kawamura M, A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/ JROSG021). Radiother Oncol. 2009; 92(2): 260-265. doi: https://doi.org/10.1016/j.radonc.2008.12.012
Versteijne E, van Laarhoven HW, van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus. 2015;28(5):453-459. doi: https://doi.org/10.1111/dote.12215.
Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81 (3):684-690. doi: https://doi.org/10.1016/j.ijrobp.2010.06.033.
NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers Version2.2019 Available from: http://www.NCCN.org [Accessed on 06 September 2019]
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20(5):1167-1174. doi: https://doi.org/10.1200/JCO.2002.20.5.1167
Suh YG, Lee IJ, Koom WS, Cha J, Lee JY, Kim SK, et al. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn J Clin Oncol. 2014;44(6):534-540. doi: https://doi.org/10.1093/jjco/hyu047.
Kim HJ, Suh YG, Lee YC, Lee SK, Shin SK, Cho BC, et al. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. Cancer Res Treat. 2017; 49 (3):669-677. doi: https://doi.org/10.4143/crt.2016.354.
Fan CY, Su YF, Huang WY, Chao HL, Lin KT, Lin CS.Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer. Sci Rep. 2018;8(1):12877. doi: https://doi.org/10.1038/s41598-018-31302-y.
Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther. 2015; 15(10):1157-1169. Epub 2015 Aug 3.
Teo MTW, McParland L, Appelt AL, Sebag-Monte-fiore D. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review.Int J Radiat Oncol BiolPhys.2018;100(1):46-158. doi: https://doi.org/10.1016/j.ijrobp.2017.09.042.
Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, et al. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(3):656-664. doi: https://doi.org/10.1016/j.ijrobp.2004.06.022
Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 2009; 92(2):266-269. doi: https://doi.org/10.1016/j.radonc.2008.09.025.
OAI - Open Archives Initiative
